Headquartered in Melbourne, Telix is an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR). The Company is developing a clinical-stage portfolio of oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. For more information visit www.telixpharma.com.